Results 131 to 140 of about 34,889 (336)

Synthesis and Evaluation of the First Generation of Glycosylated Nucleoside Analogues as Potential Inhibitors of the Base J Metabolism in Kinetoplastid Parasites

Chemistry – A European Journal, EarlyView.
Novel analogues of the kinetoplastid‐specific DNA base J unlock a new way to target parasite epigenetic regulation. Some compounds selectively inhibit Leishmania and Trypanosoma species without harming human cells, revealing a promising route toward innovative antiparasitic therapies.
Océane Monfret, Dan Liu, Manon Louis, Sihem Rebei, Dominique Urban, Yann Bourdreux, Elisabeth Mouray, Philippe Grellier, Gilles Doisneau, Dominique Guianvarc'h   +9 more
wiley   +1 more source

Porous Organic Frameworks‐Based Nanomaterials in Colorectal Cancer Therapy: From Drug Delivery to Personalized Nano‐Vaccine

Cancer Nexus, EarlyView.
ABSTRACT Colorectal cancer (CRC), as the second most common cause of cancer death worldwide, has seen a significant increase in its incidence rate in recent years. However, the current major clinical treatment methods, such as surgery, chemotherapy and radiotherapy, still have certain limitations and are difficult to achieve a complete cure.
Xiaoyu Song, Hao Zhang, Yinghui Wang, Chao Luo   +3 more
wiley   +1 more source

Activation of the Fatty Acid α-Dioxygenase Pathway during Bacterial Infection of Tobacco Leaves [PDF]

, 2003
Mats Hámberg, Ana Sanz, María Josefa Rodríguez, Angel Pablo Calvo, Carmen Castresana   +4 more
openalex   +1 more source

Indoleamine 2,3-Dioxygenase 1 (IDO1) in Kidney Transplantation: A Guardian against Rejection [PDF]

, 2023
Krzysztof Wiśnicki, Piotr Donizy, Agnieszka Hałoń, Patryk Wawrzonkowski, Dariusz Janczak, Magdalena Krajewska, Mirosław Banasik   +6 more
openalex   +1 more source

Mechanisms of Resistance to Cancer Immunotherapy: A Host–Tumor Interaction Perspective; A Review Article

Cancer Nexus, EarlyView.
Mechanisms of resistance to cancer immunotherapy from a host–tumor interaction perspective. The central tumor cell is protected by multiple resistance mechanisms, including genetic mutations, epigenetic modifications, and metabolic alterations. The immunosuppressive tumor microenvironment features myeloid‐derived suppressor cells (MDSCs), regulatory T ...
Mohammed Elmujtba Adam Essa, Hamid Noori, Abdelkareem A. Ahmed   +2 more
wiley   +1 more source

A yeast three-hybrid system that reconstitutes mammalian hypoxia inducible factor regulatory machinery [PDF]

, 2008
Background: Several human pathologies, including neoplasia and ischemic cardiovascular diseases, course with an unbalance between oxygen supply and demand ( hypoxia).
Alcaide-German, ML, Del Peso, L, Garcia-Fernandez, LF, Landazuri, MO, Vara-Vega, A   +4 more
core  

RORγt‐APCs: The New Masters of Oral Tolerance

Barrier Immunity, EarlyView.
ABSTRACT Oral tolerance is defined by the hypo‐responsiveness of our body to fed antigens, and its failure can lead to immune‐mediated diseases, such as allergy, chronic inflammation and autoimmune diseases. Decades of research have demonstrated that antigen‐presenting cells (APCs) promote oral tolerance by inducing regulatory T cells (Tregs) and/or ...
Thierry Gauthier, WanJun Chen
wiley   +1 more source

Observing 3-hydroxyanthranilate-3,4-dioxygenase in action through a crystalline lens [PDF]

, 2020
Yifan Wang, Kathy Fange Liu, Yu Yang, Ian Davis, Aimin Liu   +4 more
openalex   +1 more source

Epigenotoxicity: Decoding the epigenetic imprints of genotoxic agents and their implications for regulatory genetic toxicology

Environmental and Molecular Mutagenesis, EarlyView.
Abstract Regulatory genetic toxicology focuses on DNA damage and subsequent gene mutations. However, genotoxic agents can also affect epigenetic marks, and incorporation of epigenetic data into the regulatory framework may thus enhance the accuracy of risk assessment.
Roger Godschalk, Christopher Faulk, Jessica LaRocca, Jan van Benthem, Francesco Marchetti   +4 more
wiley   +1 more source

Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy [PDF]

Frontiers in Immunology, 2021
Lieve Brochez, Vibeke Kruse, Dirk Schadendorf, Alexander J. Muller, George C. Prendergast   +4 more
openaire   +3 more sources